Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

145,997 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial.
Liu J, Jiang Y, Zhang S, Liu S, Su J, Lin C, He X, Wu R, Yang L, Liu H, Duan X, Xu S, Luo H, Liu J, Xie Q, Mi C, Chen L, Zhang N, Gong H, Zhu J, Li Y, Wei H, Qian L, Wang J, Shi X, Jin H, Jiang Z, Xie X, Zhan F, Geng X, Zheng Z, Du Z, Dong G, Sun Y, Zeng X. Liu J, et al. Among authors: liu h, liu s. Ann Rheum Dis. 2024 Nov 27:ard-2024-226385. doi: 10.1136/ard-2024-226385. Online ahead of print. Ann Rheum Dis. 2024. PMID: 39603709
A pilot study of tofacitinib for refractory Behçet's syndrome.
Liu J, Hou Y, Sun L, Li C, Li L, Zhao Y, Zeng X, Zhang F, Zheng W. Liu J, et al. Ann Rheum Dis. 2020 Nov;79(11):1517-1520. doi: 10.1136/annrheumdis-2020-217307. Epub 2020 May 27. Ann Rheum Dis. 2020. PMID: 32461206 Clinical Trial. No abstract available.
145,997 results
You have reached the last available page of results. Please see the User Guide for more information.